Research progress on the mechanisms of combined bevacizumab and radiotherapy

Recent Patents on Anti-Cancer Drug Discovery

Volumn 9, Issue 1, 2014, Pages 129-134

  Zhuang, Hong Qing ^a   Yuan, Zhi Yong ^a   Wang, Ping ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Anti angiogenic therapies; Bevacizumab; Radiosensitivity; Radiotherapy

Indexed keywords

BEVACIZUMAB; FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CLINICAL EVALUATION; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; HUMAN; METASTASIS; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; REOXYGENATION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901284994     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/15748928113089990044     Document Type: Article

References (78)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669-76.
2. Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 1325: 541-6.
3. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89(2): 139-47.
4. Friedman GK, Spiller SE, Harrison DK, Fiveash JB, Reddy AT. Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection. J Pediatr Hematol Oncol 2013; 35(3): 123-6.
5. Blackman, R.K. Foley, K., Paul, P.D. Cancer therapy using a combination of a HSP90 inhibitory compounds and a VEGF inhibitor. US20130156755 (2013).
6. Bumcrot, D., Belmont, M.A., Akinc, A., Needham, M.A., Sah, D.W.Y., Boston, M.A., Novobrantseva, T., Cambridge, M.A. Lipid formulated compositions and methods for inhibiting expression of EG5 and VEGF genes. US20100267806 (2010).
7. Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation therapy oncology group RTOG 0411. J Clin Oncol 2009; 27(25): 4096-102.
8. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008; 71(5): 1372-1380.
9. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76(3): 824-30.
10. Kim, K.J. Antibodies to vascular endothelial cell growth factor. US7227004 (2007).
11. Fyfe, G., Holmgren, E., Mass, R.D., Novotny, W. Treatment with anti-VEGF antibodies. US7622115 (2009).
12. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65(3): 671-80.
13. Lenz, H.-J. Angiogenesis pathway gene polymorphisms for therapy selection. US7807364 (2010).
14. Kim, K.J. Methods of treating diseases with anti-VEGF antibodies. US7482005 (2009).
15. Rosen LS. VEGF-targeted therapy: Therapeutic potential and recent advances. Oncologist 2005; 10(6): 382-91.
16. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23(5): 1011-27.
17. Fuh, G., Gerber, H.-P., Liang, W.-C., Fellouse, F.A., Sidhu, S.S., Wiesmann, C. Anti-VEGF antibodies. US8092797 (2012).
18. Ramachandra, S., Bishop, W.R., Masat, L., Huang, C.B., Takeuchi, T., Kantak, S., Huang, C.-Y. Fully human anti-VEGF antibodies and methods of using. US8216571 (2012).
19. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002; 9(s2): 36-44.
20. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7(4): 335-45.
21. Zhuang HQ, Yuan ZY. Process in the mechanisms of endostatin combined with radiotherapy. Cancer Lett 2009(1); 282: 9-13.
22. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc Res 2007; 74(2-3): 72-84.
23. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: Novel insights through intravital imaging in pre clinical models. Microcirculation 2010; 17(3): 206-25.
24. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
25. Jain RK, Finn AV, Kolodgie FD, Gold HK, Virmani R. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: A potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 2007; 4(5706): 491-502.
26. Wildiers H, Guetens G, De BG, Verbeken E, Landuyt B, Landuyt W, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88(12): 1979-86.
27. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: Promise and challenge. Curr Pharm Des 2007; 13(35): 3545-58.
28. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801): 249-57.
29. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
30. Carmeliet P. VEGF gene therapy: Stimulating angiogenesis or angioma-genesis. Nat Med 2000; 6: 1102-103.
31. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5(10): 816-26.
32. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002; 295(5559): 1526-8.
33. Kerbel RS. Antiangiogenic therapy: A universal chemosensitization strategy for cancer Science 2006; 312 (5777): 1171-5.
34. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion Cell 2005; 121(3): 335-48.
35. Lin EY, Li JF, Gnatovskiy L, Yan D, Liyin Z, Dustin AG. et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006; 66(23): 11238-46
36. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64(22): 8249-55.
37. Zhuang HQ, Sun J, Yuan ZY, Wang J, Zhao LJ, Wang P, et al. Radiosensitizing effects of gefitinib at different administration times in vitro. Cancer Sci 2009; 100(8): 1520-5.
38. McIlwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res 1994; 54(14): 3718-22.
39. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat Rev Cancer 2005; 5(7): 516-25.
40. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63(14): 4009-16.
41. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999; 13(1): 9-22.
42. Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, Debus JU, et al. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys 2004; 60(4): 1220-32.
43. Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003; 63(13): 3755-63.
44. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6(6): 553-63.
45. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64(11): 3731-6.
46. Jain RK, Finn AV, Kolodgie FD, Gold HK, Virmani R. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: A potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 2007; 4(9): 491-502.
47. Wen QL, Meng MB, Yang B, Tu LL, Jia L, Zhou L, et al. Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci 2009; 100(8): 1510-9.
48. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307(5706): 58-62.
49. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc Res 2007; 74(2-3): 72-84.
50. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. Oncologist 2004;9 Suppl1: 36-42.
51. Wachsberger P, Burd R, Dicker AP. Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am 2004; 18 (5):1039-57.
52. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction. Clin Cancer Res 2003; 9(6): 1957-71.
53. Willett CG, Kozin SV, Duda DG, Di TE, Kozak KR, Boucher Y, et al. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice. Semin Oncol 2006; 33(5 Suppl 10): S35-40.
54. Cosgrove D. Angiogenesis imaging ultrasound. Br J Radiol 2003; 76(1): S43-49.
55. Padhani AR, Harvey CJ, Cosgrove DO. Angiogenesis imaging in the management of prostate cancer. Nat Clin Pract Urol 2005; 2(12): 596-607.
56. Forsberg F, Ro RJ, Potoczek M, Liu JB, Merritt CR, James KM, et al. Assessment of angiogenesis: Implications for ultrasound imaging. Ultrasonics 2004; 42(1-9): 325-30.
57. Kothari M, Guermazi A, White D, Suhy J, Reinhold C. Imaging in antiangiogenesis trial: A clinical trials radiology perspective. Br J Radiol 2003; 76 (Spec No 1): S92-96.
58. Schirner M, Menrad A, Stephens A, Frenzel T, Hauff P, Licha K. Molecular imaging of tumor angiogenesis. Ann N Y Acad Sci 2004; 1014: 67-75.
59. Padhani AR. Dynamic contrast enhanced MRI in clinical oncology: Current status and future directions. J Magn Reson Imaging 2002; 16(4): 407-22.
60. Padhani AR, Husband JE. Dynamic contrast enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001; 56(8): 607-20.
61. Myers AL, Williams RF, Ng CY, Hartwich JE, Davidoff AM. Bevacizumab induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg 2010; 45(6): 1080-5.
62. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57(5): 963-69.
63. Mayer R, Handl-Zeller L, Quehenberger F, Hammer J, Kametriser G, Kolbabek H, et al. Patterns of care in radiotherapy of breast cancer in Austria 1985: Data acquisition and comparison with data of US-PCS 1983. Radiother Oncol 2004; 72(1): 45-51.
64. Kieran MW, Folkman J, Heymach J. Angiogenesis inhibitors and hypoxia. Nat Med 2003; 9(9):1104-5.
65. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10(8): 789-99.
66. Dang LH, Bettegowda C, Agrawal N, Cheong I, Huso D, Frost P, et al. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 2004; 3(3): 326-37.
67. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105(8): 1045-7.
68. Bagri A, Kouros-Mehr H, Leong KG, Plowman GD. Use of anti-VEGF adjuvant therapy in cancer: Challenges and rationale. Trends Mol Med 2010; 16(3): 122-32.
69. Giovannoni, L. Process for selecting anti-angiogenesis antibody fragments, anti-angiogenesis antibody fragments thus obtained and their use. US7723269 (2010).
70. Waisman, D., Kwon, M. Anti-angiogenesis methods, compositions and uses therefore. US7250271 (2007).
71. Shima, D., Calias, P, Adamis, AP. Combination therapy for the treatment of ocular neovascular disorders. US8187597 (2012).
72. Cao, L., Davis, T.W., Romfo, C.M., Trotta, C.R. Inhibition of VEGF translation. US8076353 (2012).
73. D'Amato, R.J. Methods and compositions for inhibition of angiogenesis. US8039488 (2011).
74. Moore, J., Keyt, B., Burnier, J., Sherman, B.M., Totrov, M., Ossovskaya, V.S. Treatment of cancer. US8143447 (2012).
75. Garovic, V.D. Early maker of proteinuria in patients treated with an anti-VEGF treatment. US20130034861 (2013).
76. Andres, H., De, H.S.L., Elliott, R., Karl, J., Meng, Y.-J.G., Plowman, G.D., Scherer, S., Wild, N. Blood plasma biomarkers for bevacizumab combination therapies for breast cancer. WO2013083499 (2013).
77. Delmar, P., Foernzler, D., Scherer, S. Neuropilin as a biomarker for Bevacizumab combination therapies. US20130171134 (2013).
78. Weisenthal, L.M. Treatment protocol. US20130011396 (2013).